すべての画像(1)
About This Item
実験式（ヒル表記法）:
C22H18N2
CAS番号:
分子量:
310.39
EC Number:
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77
おすすめの製品
品質水準
アッセイ
≥98% (HPLC)
フォーム
powder
色
white to off-white
溶解性
DMSO: >10 mg/mL
オーガナイザー
Bayer
保管温度
room temp
SMILES記法
c1ccc(cc1)C(c2ccc(cc2)-c3ccccc3)n4ccnc4
InChI
1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
InChI Key
OCAPBUJLXMYKEJ-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
生物化学的／生理学的作用
Bifonazole is an imidazole-based anti-fungal agent with broad spectrum activity against many fungi, molds, yeast and some Gram-positive bacteria. Bifonazole inhibits ergosterol biosynthetic protein 28 and Cytochrome P450 2B4.
Bifonazole is used to treat several infections such as onychomycoses, otomycoses, erythrasma, psoriasis, sebopsoriasis, seborrhoeic dermatitis and rosacea. Bifonazole is also used as an important drug to treat melanoma.
特徴および利点
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
B3563-10MG:
B3563-VAR:
B3563-50MG:
B3563-BULK:
最新バージョンのいずれかを選択してください：
Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells
Penso J and Beitner R
European Journal of Pharmacology, 342(1), 113-117 (1998)
Sai Hu et al.
International journal of molecular medicine, 47(5) (2021-03-12)
Radioresistance is the predominant cause for radiotherapy failure and disease progression, resulting in increased breast cancer‑associated mortality. Using gene expression signature analysis of the Library of Integrated Network‑Based Cellular Signatures (LINCS) and Gene Expression Omnibus (GEO), the aim of the
Shinichi Watanabe et al.
Mycoses, 49(3), 236-241 (2006-05-10)
The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34
Nehama Linder et al.
Birth defects research. Part A, Clinical and molecular teratology, 88(3), 201-204 (2009-12-17)
Neonatal limb reduction defects may be caused by exposure to an external agent. The azole derivatives are used in the treatment of systemic and dermal mycoses. Their relative teratogenic risk is still controversial. We describe two newborns with severe limb
P Ross Wilderman et al.
The FEBS journal, 279(9), 1607-1620 (2011-11-05)
Residues located outside the active site of cytochromes P450 2B have exhibited importance in ligand binding, structural stability and drug metabolism. However, contributions of non-active-site residues to the plasticity of these enzymes are not known. Thus, a systematic investigation was
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）